Beijing Tiantan Biological Products Corp Ltd
SSE:600161

Watchlist Manager
Beijing Tiantan Biological Products Corp Ltd Logo
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Watchlist
Price: 20.52 CNY -1.2% Market Closed
Market Cap: 40.6B CNY
Have any thoughts about
Beijing Tiantan Biological Products Corp Ltd?
Write Note

Operating Margin
Beijing Tiantan Biological Products Corp Ltd

38.3%
Current
32%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.3%
=
Operating Profit
2B
/
Revenue
5.2B

Operating Margin Across Competitors

Country CN
Market Cap 40.6B CNY
Operating Margin
38%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 311.8B USD
Operating Margin
28%
Country US
Market Cap 140.7B USD
Operating Margin
19%
Country US
Market Cap 115.7B USD
Operating Margin
38%
Country US
Market Cap 102.7B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Beijing Tiantan Biological Products Corp Ltd
Glance View

Market Cap
40.6B CNY
Industry
Biotechnology

In the bustling heart of China's biotech industry, Beijing Tiantan Biological Products Corp Ltd emerges as a key player in the crucial field of vaccine and blood product innovations. Rooted in the expansive landscape of pharmaceutical development, the company sets its focus on producing essential vaccines—including those for hepatitis B—and blood-derived products such as albumin, immunoglobulin, and coagulation factor. These products play pivotal roles in preventative healthcare and in treating various diseases. Tiantan Bio operates with a robust integration of research and manufacturing expertise, underpinned by a deep commitment to public health advancement. The company continuously seeks to expand its product offerings, refining processes through relentless research and development to meet the demands of both domestic and international markets. Earnings for Tiantan Biological flow primarily from the successful commercialization of its vaccines and blood products. The company establishes strategic partnerships with research institutions and leverages government healthcare policies that favor domestic vaccine consumption to bolster its market position. Tiantan Bio also invests significantly in infrastructure to upscale its production capabilities, responding to the growing demand for its products. Their business model capitalizes on the symbiotic relationship between research innovation and market needs, ensuring a steady stream of revenue through both public procurement and private healthcare partnerships. This strategic orientation not only showcases its influence in the biotech sphere but also reflects its adaptability and foresight in navigating the dynamic landscape of global healthcare challenges.

Intrinsic Value
25.18 CNY
Undervaluation 19%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.3%
=
Operating Profit
2B
/
Revenue
5.2B
What is the Operating Margin of Beijing Tiantan Biological Products Corp Ltd?

Based on Beijing Tiantan Biological Products Corp Ltd's most recent financial statements, the company has Operating Margin of 38.3%.